Core Insights - The stock price of Haitai Newlight closed at 35.19 yuan, up 1.85%, with a rolling PE ratio of 29.56, marking a 20-day low, and a total market capitalization of 4.244 billion yuan [1] - In the medical device industry, the average PE ratio is 48.90, with a median of 36.41, placing Haitai Newlight at the 66th position [1] - As of the first quarter of 2025, 26 institutions hold shares in Haitai Newlight, including 22 funds, 3 others, and 1 social security fund, with a total holding of 57.068 million shares valued at 2.145 billion yuan [1] Company Overview - Qingdao Haitai Newlight Technology Co., Ltd. specializes in the research, development, production, sales, and service of medical endoscope instruments and optical products [1] - The main products include high-definition fluorescence endoscope instruments, high-definition white light endoscope instruments, endoscope accessories, and endoscope maintenance services [1] - The company has achieved significant technological advancements in the field of medical endoscope instruments and optical products, holding 37 domestic and international invention patents and undertaking several key national and provincial science and technology projects [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 147 million yuan, a year-on-year increase of 24.86%, and a net profit of 46.6887 million yuan, up 21.45%, with a gross profit margin of 64.98% [1]

截至2025年一季报，共有26家机构持仓海泰新光，其中基金22家、其他3家、社保1家，合计持股数 5706.80万股，持股市值21.45亿元。 青岛海泰新光科技股份有限公司主营业务为医用内窥镜器械和光学产品的研发、生产、销售和服务。公 司主要产品分为高清荧光内窥镜器械、高清白光内窥镜器械、内窥镜器械配件、内窥镜器械维修等。公 司多年来在医用内窥镜器械领域和光学产品领域技术上不断开拓创新，在该领域实现了多项核心技术， 获得国内外发明专利37项，先后承担了多项国家及省市重点科技项目。 最新一期业绩显示，2025年一季报，公司实现营业收入1.47亿元，同比24.86%；净利润4668.87万元， 同比21.45%，销售毛利率64.98%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)69海泰新光29.2130.983.1241.94亿行业平均 46.4044.004.49100.23亿行业中值34.8137.612.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155. ...